Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry

Abstract

Maspin belongs to the serine protease inhibitor (serpin) family and has been proven to be a suppressor of tumor growth and metastasis in many types of tumors. The purpose of this study was to investigate the expression of maspin in non-small cell lung cancer (NSCLC) and its relationship to vasculogenic mimicry (VM). A total of 160 specimens of NSCLC were involved in this study and 20 specimens of normal lung tissue served as controls. VM, microvessel density (MVD) and the expression of maspin were detected by using immunohistochemical staining. The results showed that the positive rates of maspin and VM in the NSCLC group were 48.1% (77/160) and 36.9% (59/160), respectively, which were significantly different from those in the control group with the positive rates of maspin and VM being 100% and 0% respectively (P<0.05). VM, MVD and the expression level of maspin were significantly related to tumor differentiation, lymph node metastasis, clinical stages and postoperative survival time (all P<0.05). The maspin expression in patients with squamous cell carcinoma was significantly higher than that in those with adenocarcinoma (P<0.05). The maspin expression was negatively correlated with VM and MVD, and there was a positive correlation between VM and MVD. Maspin-negative expression, VM and high MVD score were negatively related to the 5-year-survival rate. PTNM stages, VM, MVD and maspin expression were independent prognostic factors for NSCLC (P<0.05). It was suggested that the loss of expression of maspin may participate in the invasion and metastasis of NSCLC and it has a positive relationship to VM in NSCLC. Combined detection of maspin, VM and MVD may help predict the progression and prognosis of NSCLC.

Keywords

non-small cell lung cancer / maspin / vasculogenic mimicry / microvessel density / prognosis

References

[1] JemalA., CenterM.M., DesantisC., et al.. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 2010, 19(8): 1893-1907

[2] RamalingamS.S., OwonikokoT.K., KhuriF.R.. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin, 2011, 61(2): 91-112

[3] ZouZ., AnisowiczA., HendrixM.J., et al.. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 1994, 263(5146): 526-529

[4] NgamkitidechakulC., WarejckaD.J., BurkeJ.M., et al.. Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. Conversion of ovalbumin to a maspin-like molecule. J Biol Chem, 2003, 278(34): 31796-31806

[5] Odero-MarahV.A., Khalkhali-EllisZ., ChunthapongJ., et al.. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cell. Cancer Biol Ther, 2003, 2(4): 398-403

[6] LiuJ., YinS., ReddyN., et al.. Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res, 2004, 64(5): 1703-1711

[7] ZhangW., ShiH.Y., ZhangM.. Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer, 2005, 5: 50

[8] BaileyC.M., Khalkhali-EllisZ., SeftorE.A., et al.. Biological functions of maspin. J Cell Physiol, 2006, 209(3): 617-624

[9] ShengS.. A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge. J Cell Physiol, 2006, 209(3): 631-635

[10] Khalkhali-EllisZ.. Maspin, the new frontier. Clin Cancer Res, 2006, 12(24): 7279-7283

[11] ManiotisA.J., FolbergR., HessA., et al.. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol, 1999, 155(3): 739-752

[12] SoodA.K., SeftorE.A., FletcherM.S., et al.. Molecular determinants of ovarian cancer plasticity. Am J Pathol, 2001, 158(4): 1279-1288

[13] HeymanL., Leroy-DudalJ., FemandsJ., et al.. Mesothelial vitronectin stimulates migration of ovarian cancer cell. Cell Biol Int, 2010, 34(5): 493-502

[14] ZhaoX.L., DuJ., ZhangS.W., et al.. A study on vasculogenic mimicry in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi (Chinese), 2006, 14(1): 41-44

[15] GuzmanG., CotlerS.J., LinA.Y., et al.. A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med, 2007, 131(12): 1776-1781

[16] LiuW.B., XuG.L., MaJ.L., et al.. Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma. Tohoku J Exp Med, 2011, 224(1): 29-39

[17] GrayD.R., HussW.J., YauJ.M., et al.. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res, 2004, 64(5): 1712-1721

[18] AhmadiS.A., MoinfarM., Gohari MoquaddamK., et al.. Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma. Arch Iran Med, 2010, 13(6): 498-503

[19] FanY.Z., SunW., ZhangW.Z., et al.. Vasculogenic mimicry in human primary gallbladder carcinoma and clinical significance thereof. Zhonghua Yi Xue Za Zhi, 2007, 87(3): 145-149

[20] LiM., GuY., ZhangZ., et al.. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res, 2010, 16(2): 259-266

[21] VartanianA.A., StepanovaE.V., GutorovS.L., et al.. Prognostic significance of periodic acid-schiff-positive patterns in clear cell renal cell carcinoma. Can J Urol, 2009, 16(4): 4726-4732

[22] ShirakawaK., WakasugiH., HeikeY., et al.. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer, 2002, 99(6): 821-828

[23] BasuG.D., LiangW.S., StephanD.A., et al.. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cell. Breast Cancer Res, 2006, 8(6): R69

[24] YueW.Y., ChenZ.P.. Does vasculogenic mimicry exist in astrocytoma?. J Histochem Cytochem, 2005, 53(8): 997-1002

[25] KumadaT., TsuneyamaK., HattaH., et al.. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol, 2004, 17(9): 1141-1149

[26] FolbergR., ManiotisA.J.. Vasculogenic mimicry. APMIS, 2004, 112(7–8): 508-525

[27] ToillonR.A., LagadecC., PageA., et al.. Proteomics demonstration that normal breast epithelial cells can induce apoptosis of breast cancers through insulin-like growth factor-binding protein-3 and maspin. Mol Cell Proteomics, 2007, 6(7): 1239-1247

[28] LonardoF., LiX., KaplunA., et al.. The natural tumor suppressor protein maspin and potential application in non-small cell lung cancer. Curr Pharm Des, 2010, 16(16): 1877-1881

[29] KimS., HanJ., KimJ., et al.. Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Res, 2004, 64(19): 6900-6905

[30] NamE., ParkC.. Maspin suppresses survival of lung cancer cells through modulation of Akt pathway. Cancer Res Treat, 2010, 42(1): 42-47

[31] TakanamilI., AbikoT., KoizumiS., et al.. Expression of maspin in non-small-cell lung cancer correlation with clinical features. Clin Lung Cancer, 2008, 9(6): 361-366

[32] NiJ.T., YiY.F., ShiH.P.. Expression of maspin, p53 and Skp2 in colorectal tumors and their clinicopathological significance. Chin J Cancer Res, 2009, 21(2): 147-153

[33] FanY.Z., SunW.. Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg, 2010, 2(4): 117-127

[34] ZhangS., GuoH., ZhangD., et al.. Microcirculation patterns in different stages of melanoma growth. Onclo Rep, 2006, 15(1): 15-20

[35] ForbergR., HendrixM.J., ManiotisA.J.. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol, 2000, 156(2): 361-381

[36] MineoT.C., AmbrogiV., BaldiA., et al.. Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol, 2004, 57(6): 591-597

[37] WangM.C., YangY.M., LiX.H., et al.. Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer. World J Gastroenterol, 2004, 10(5): 634-637

[38] SoodA.K., FletcherM.S., CoffinJ.E., et al.. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol, 2004, 190(4): 899-909

[39] SunB., ZhangS., ZhaoX., et al.. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol, 2004, 25(6): 1609-1614

[40] WangW., LinP., HanC.H., et al.. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res, 2010, 29: 60

[41] NakashimaM., OhikeN., NagasakiK., et al.. Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma. J Cancer Res Clin Oncol, 2004, 130(8): 475-479